Mesoblast reports 44% revenue growth and 86% cash spend improvement in Q1 FY2027, advancing key clinical trials.

Mesoblast Limited announced a 44% increase in net revenues to $28 million and an 86% reduction in net operational cash spend to $2.1 million for the first fiscal quarter ended September 30, 2026. The company completed patient treatment in a Phase 3 trial for chronic low back pain and had a positive FDA meeting on a Biologics License Application for a heart failure treatment. Mesoblast continues to expand its Ryoncil product use and manufacturing capabilities, positioning for future growth in inflammatory and cardiovascular disease therapies. Cash reserves stood at $99 million, supporting ongoing clinical and commercial activities.

Mesoblast Limited's stock price rose sharply by 9.26% to USD 14.40 on Pluang as of Oct 29, 2026 07:11 WIB, reflecting strong market interest following the company's positive operational results and clinical progress. The stock's market cap stands at $1.69 billion, with a typical hold time of 17 days on the platform. This trading activity highlights investor attention to Mesoblast amid its expanding product pipeline and financial improvements.